Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 7/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.33 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13089119 | 0.90 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3CFTRGOPC | |
| SCHEMBL3069737 | 0.88 | CYP19A1 (0.40) | SLC6A2SLC6A4SLC6A3CFTRGOPC | |
| SCHEMBL13089174 | 0.85 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3CYP19A1HDAC4 | |
| SCHEMBL13089142 | 0.84 | GAA (0.52) | SLC6A2SLC6A4SLC6A3CFTRGOPC | |
| SCHEMBL13089180 | 0.83 | SLC6A2 (0.61) | SLC6A2SLC6A4SLC6A3CFTRGOPC | |
| SCHEMBL13089064 | 0.81 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3CFTRGOPC | |
| SCHEMBL13089100 | 0.81 | IDO1 (0.38) | SLC6A2SLC6A4SLC6A3CFTRGOPC | |
| SCHEMBL13089094 | 0.80 | GAA (0.44) | SLC6A2SLC6A4SLC6A3CFTRGOPC | |
| SCHEMBL13089104 | 0.80 | KCNA5 (0.45) | SLC6A2SLC6A4SLC6A3CFTRGOPC | |
| SCHEMBL13089168 | 0.79 | CFTR (0.41) | SLC6A2SLC6A4SLC6A3CFTRGOPC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273814-A1 | ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS | SINHA SANTOSH C | 2010-10-28 | — | — | US | disclosed |
| US-20100273814-A1 | ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS | SINHA SANTOSH C | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273814-A1 | ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS | CYP11B2, TPMT, COXFA4L2 | SLC6A2 2046/4885SLC6A4 1930/4885SLC6A3 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.